Navigation Links
Par Pharmaceutical Announces Outcome of the Litigation With Pentech Pharmaceuticals
Date:2/10/2009

WOODCLIFF LAKE, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that on February 9, 2009, following a bench trial, the district court entered a judgment in favor of Pentech Pharmaceuticals, Inc. and against Par in the amount of $69,955,476. As a result of the court's decision, Par will accrue additional reserves of approximately $28 million on an after-tax basis in the fourth quarter of 2008.

As previously disclosed, on May 3, 2004, Pentech filed an action against the Company in the United States District Court for the Northern District of Illinois. This action alleged that Par breached its contract with Pentech relating to the supply and marketing of paroxetine (Paxil(R)).

Par and its counsel received the court's decision yesterday afternoon and are considering the Company's options for appeal.

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2007, in Item 1A of the Company's subsequent Quarterly Reports on Form 10-Q, in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mpex Pharmaceuticals Announces Series D Financing of Up to $40 Million
2. HealthLeaders-InterStudy Offers District Survival Kit to Arm Pharmaceutical Sales Teams With Local-Level Managed Care Market Intelligence
3. Compass Pharma Services Offers Microfill Capabilities to Contract Pharmaceutical Packaging Customers
4. Prism Pharmaceuticals Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
5. Best Practice Database adds Research Highlighting the Value of Internal Consulting and Early-Stage Commercialization Groups in the Pharmaceutical Industry
6. KV Pharmaceutical Company Reduces Workforce
7. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
8. Consumer Advocates Call on Legislature to Support Governors Ban on Pharmaceutical Gifts to Doctors
9. Pharmaceuticals sold in Sweden cause serious environmental harm in India
10. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
11. Shengtai Pharmaceutical, Inc. Comments on Chinas Recently Approved Health Care Reform Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Hospital M&A activity slowed in the ... number of hospital acquisitions rose to 23 in the second quarter, up 15% from ... from the 20 announced deals in the year-ago second quarter. Only four of the ...
(Date:7/21/2017)... ... ... The House of Yahweh in Abilene, Texas, has written a new post this week that ... to be more open about positive changes. Yisrayl says the use of force is not ... positive way to solve all; yes, all issues, and he is ready to share this ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing ... tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation ... launches on Kickstarter on Monday, July 21st. , The kit uses colorful, engaging ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... with over 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome ... knee-related quality of life a decade after surgery, though activity levels decline over ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is ... clips in the FCPX timeline. This effect isolates horizontal and vertical lines of pixels ... contains either a rotating or flipping animation and can be changed using a drop-down ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... , July 5, 2017 Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... it has received approval from the Israel Securities Authority to ... (TASE). Oramed common stock will commence trading on the TASE ... the current market capitalization of the Company, it is expected ...
(Date:7/1/2017)... WARSAW, Ind. , June 30, 2017 Zimmer ... second quarter sales and earnings conference call will be broadcast ... 8 a.m. Eastern Time.  A news release detailing the quarterly ... the morning of the conference call. The live ... website at http://investor.zimmerbiomet.com . It will be archived for ...
(Date:6/30/2017)... , June 29, 2017  Axium Pharmaceuticals Inc. is a pharmaceutical ... novel formulations and alternative dosage forms of existing biologically active ... ... on our waterless self-nano emulsifying formula, which is designed to ... We believe the spray will provide fast onset of action ...
Breaking Medicine Technology: